DVA * Stock Overview
Provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DaVita Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3,113.21 |
| 52 Week High | US$3,113.21 |
| 52 Week Low | US$2,195.00 |
| Beta | 0.89 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 35.36% |
| 5 Year Change | 131.81% |
| Change since IPO | 132.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| DVA * | MX Healthcare | MX Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | -1.0% |
| 1Y | n/a | -15.6% | -3.3% |
Return vs Industry: Insufficient data to determine how DVA * performed against the MX Healthcare industry.
Return vs Market: Insufficient data to determine how DVA * performed against the MX Market.
Price Volatility
| DVA * volatility | |
|---|---|
| DVA * Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 5.9% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.6% |
Stable Share Price: DVA *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine DVA *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 70,000 | Javier Rodriguez | www.davita.com |
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
DaVita Inc. Fundamentals Summary
| DVA * fundamental statistics | |
|---|---|
| Market cap | Mex$275.68b |
| Earnings (TTM) | Mex$16.81b |
| Revenue (TTM) | Mex$257.29b |
16.5x
P/E Ratio1.1x
P/S RatioIs DVA * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DVA * income statement (TTM) | |
|---|---|
| Revenue | US$12.67b |
| Cost of Revenue | US$8.51b |
| Gross Profit | US$4.16b |
| Other Expenses | US$3.33b |
| Earnings | US$827.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.09 |
| Gross Margin | 32.80% |
| Net Profit Margin | 6.53% |
| Debt/Equity Ratio | 419.9% |
How did DVA * perform over the long term?
See historical performance and comparison